PHILADELPHIA, March 26, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc. (NYSE Amex:HEB) announced the publication of a peer-reviewed article in the Journal of Interferon and Cytokine Research (Volume 32, pages 95-102) providing an analysis of the incidence and clinical impact of neutralizing antibodies (NABs) formed during treatment with recombinant interferons (a-2a, a-2b, ß-1a and ß-1b) compared to natural interferons (a-n1 or a-n3), such as Alferon N Injection®. The recombinant interferons induced seroconversion with the generation of NABs in 17.2% of patients studied. Seroconversion is the development of detectable specific antibodies. Antibodies can sometimes attack a pharmaceutical administered to the body eventually inhibiting the effect of the medication.
